A Berezovskaya - JoVE Visualize

Showing results (1-10 of 13) with videos related to

Pageof 2

Sort By:

Journal of Immunology (Baltimore, Md. : 1950)|December 22, 1999

CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progressionL J Appleman, A Berezovskaya, I Grass, et al.

Science (New York, N.Y.)|October 6, 1997

Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1V A Boussiotis, G J Freeman, A Berezovskaya, et al.

Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1998

CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic miceS C Henderson, A Berezovskaya, A English, et al.

Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1995

Regulated expression of Ly-6A.2 is important for T cell developmentA Bamezai, D Palliser, A Berezovskaya, et al.

Nature Medicine|March 4, 2000

p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytesV A Boussiotis, G J Freeman, P A Taylor, et al.

Blood|January 12, 2001

Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-beta-treated alloreactive T cells that do not induce graft-versus-host diseaseV A Boussiotis, Z M Chen, J C Zeller, et al.

Nature Immunology|November 6, 2001

Tob is a negative regulator of activation that is expressed in anergic and quiescent T cellsD Tzachanis, G J Freeman, N Hirano, et al.

The Journal of Clinical Investigation|May 3, 2000

IL-10-producing T cells suppress immune responses in anergic tuberculosis patientsV A Boussiotis, E Y Tsai, E J Yunis, et al.

Frontiers in Psychiatry|December 12, 2022

Salivary oxytocin in autistic patients and in patients with intellectual disabilityYulia A Pichugina, Irina V Maksimova, Marina A Berezovskaya, et al.

Leukemia|May 24, 2016

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cellsJ Etchin, A Berezovskaya, A S Conway, et al.

Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:

Pageof 2

Journal of Immunology (Baltimore, Md. : 1950)|December 22, 1999

CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progressionL J Appleman, A Berezovskaya, I Grass, et al.

Science (New York, N.Y.)|October 6, 1997

Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1V A Boussiotis, G J Freeman, A Berezovskaya, et al.

Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1998

CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic miceS C Henderson, A Berezovskaya, A English, et al.

Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1995

Regulated expression of Ly-6A.2 is important for T cell developmentA Bamezai, D Palliser, A Berezovskaya, et al.

Nature Medicine|March 4, 2000

p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytesV A Boussiotis, G J Freeman, P A Taylor, et al.

Blood|January 12, 2001

Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-beta-treated alloreactive T cells that do not induce graft-versus-host diseaseV A Boussiotis, Z M Chen, J C Zeller, et al.

Nature Immunology|November 6, 2001

Tob is a negative regulator of activation that is expressed in anergic and quiescent T cellsD Tzachanis, G J Freeman, N Hirano, et al.

The Journal of Clinical Investigation|May 3, 2000

IL-10-producing T cells suppress immune responses in anergic tuberculosis patientsV A Boussiotis, E Y Tsai, E J Yunis, et al.

Frontiers in Psychiatry|December 12, 2022

Salivary oxytocin in autistic patients and in patients with intellectual disabilityYulia A Pichugina, Irina V Maksimova, Marina A Berezovskaya, et al.

Leukemia|May 24, 2016

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cellsJ Etchin, A Berezovskaya, A S Conway, et al.

Pageof 2